Standard Chemotherapy with Excluding Isoniazid in a Murine Model of Tuberculosis
![]() ![]() |
Shim, Tae Sun
(Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Lee, Eun Gae (Department of Microbiology and the Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine) Choi, Chang Min (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Hong, Sang-Bum (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Oh, Yeon-Mok (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Lim, Chae-Man (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Lee, Sang Do (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Koh, Younsuck (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Kim, Woo Sung (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Kim, Dong Soon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Cho, Sang-Nae (Department of Microbiology and the Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine) Kim, Won Dong (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) |
1 | Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133: 423-30. |
2 | Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-54. DOI ScienceOn |
3 | Roberts AD, Cooper AM, Beslisle JT, Turner J, Gonzalez- Juarrero M, Orme IM. Murine model of tuberculosis. In: Kaufmann SHE, Kabelitz D, editors. Methods in microbiology, Vol. 32. New York: Elsevier Sciences; 2002. p. 433. |
4 | Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006;50:2621-5. DOI |
5 | Centers for Disease Control and Prevention, American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9. |
6 | Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140: 1189-93. DOI ScienceOn |
7 | Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002;51:998-9. |
8 | Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamiderifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-51. DOI ScienceOn |
9 | Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection-- New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001;50:289-91. |
10 | Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169:421-6. DOI ScienceOn |
11 | Bai GH. Anti-tuberculosis drug resistance in Korea. Commun Dis Month Rep 2005;16:101-7. |
12 | Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, et al. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med 2005;172:1457-62. DOI ScienceOn |
13 | American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1-77. |
![]() |